FundaMental Pharma

📍 Heidelberg, Germany🗓 Founded 2016👥 12 employees💰 Last funded Sep 2022
Biotechnology Research🌐 fundamentalpharma.com
Website LinkedIn
FundaMental Pharma is engaged in pioneering research around a breakthrough molecular mechanism that allows to safely counteract glutamate neurotoxicity (also known as excitotoxicity) by specifically targeting the interface between NMDA receptors and TRPM4 channels with small molecule TwinF interface inhibitors (Yan et al., Science 2020). TwinF interface inhibitors constitute an entirely new class of drugs that safely ameliorate glutamate neurotoxicity, a common cause of neurodegeneration. Our initial focus is on amyotrophic lateral sclerosis (ALS). The applicability of our molecules extends to a range of neurogenerative disorders including Alzheimer’s disease (AD).
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2016
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
2
Frequently asked questions
Who invested in FundaMental Pharma?
FundaMental Pharma has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did FundaMental Pharma last raise funding?
The most recent investment in FundaMental Pharma recorded on gritt.io was in September 2022.
When was FundaMental Pharma founded?
FundaMental Pharma was founded in 2016.
What industry is FundaMental Pharma in?
FundaMental Pharma operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is FundaMental Pharma based?
FundaMental Pharma is headquartered in Heidelberg, Germany.